Key Features

  • Brain volume change
  • Report generation
  • White matter abnormality quantification

General Information

Product name

icobrain ms

Company

Subspeciality

Neuro

Modality

MR

Disease targeted

Multiple sclerosis

Main task

Not specified

Technical Specifications

Population

multiple sclerosis patients

Patient population age

Not specified

Input

For MRI: 3D T1 weighted image and 3D FLAIR

Input format

DICOM

Output

Color-coded segmentation overlays, concise reports with reference statistics, pre-populated radiological reporting template

Output format

DICOM

Integration

Integration in standard reading environment (PACS), Integration RIS (Radiological Information System), Integration via AI marketplace or distribution platform

Deployment

Cloud-based

Trigger for analysis

Automatically, Etc., Image upload, On demand, Right after the image acquisition, Triggered by a user through e.g. a button click

Processing time

> 10 minutes

Regulatory Information

CE Certification

Pathway:

MDR

Class:

Class IIa

Verified by Health AI Register
FDA Certification

Pathway:

510(k) cleared

Class:

Class II

Verified by Health AI Register

Other certifications

Not specified

Market Presence

On market since

2016

AI Platforms

Bayer Pharmaceuticals, Blackford Analysis, GE Healthcare, Intrasense, Nuance

Resellers

Not specified

Countries present

23

Paying clinical customers

>100

Research/test users

>300

Pricing Information

Pricing model

Subscription

Based on

Number of analyses

Evidence & Research

Peer-Reviewed Papers

Peer-Reviewed

View

Reliable measurements of brain atrophy in individual patients with multiple sclerosis

Peer-Reviewed

View

Two Time Point MS Lesion Segmentation in Brain MRI: An Expectation-Maximization Framework

Peer-Reviewed

View

icobrain ms 5.1: Combining unsupervised and supervised approaches for improving the detection of multiple sclerosis lesions

Other Articles

Other

View

A Novel Digital Care Management Platform to Monitor Clinical and Subclinical Disease Activity in Multiple Sclerosis

Source: vendor | First published: May 26, 2024 | Last updated: Jul 9, 2025